These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7834438)

  • 1. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings.
    Crowe JP; Adler LP; Shenk RR; Sunshine J
    Ann Surg Oncol; 1994 Mar; 1(2):132-40. PubMed ID: 7834438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
    J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
    Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
    Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
    Utech CI; Young CS; Winter PF
    Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
    Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
    Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease.
    Tse NY; Hoh CK; Hawkins RA; Zinner MJ; Dahlbom M; Choi Y; Maddahi J; Brunicardi FC; Phelps ME; Glaspy JA
    Ann Surg; 1992 Jul; 216(1):27-34. PubMed ID: 1632699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
    Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
    Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.
    Nieweg OE; Kim EE; Wong WH; Broussard WF; Singletary SE; Hortobagyi GN; Tilbury RS
    Cancer; 1993 Jun; 71(12):3920-5. PubMed ID: 8389655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
    Basu S; Mavi A; Cermik T; Houseni M; Alavi A
    Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
    Smith IC; Ogston KN; Whitford P; Smith FW; Sharp P; Norton M; Miller ID; Ah-See AK; Heys SD; Jibril JA; Eremin O
    Ann Surg; 1998 Aug; 228(2):220-7. PubMed ID: 9712568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
    Alberini JL; Lerebours F; Wartski M; Fourme E; Le Stanc E; Gontier E; Madar O; Cherel P; Pecking AP
    Cancer; 2009 Nov; 115(21):5038-47. PubMed ID: 19645022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
    Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
    Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.